Skip to main content

Peer Review reports

From: Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/β-catenin signal pathway in prostate cancer cells

Original Submission
20 Mar 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
9 Apr 2021 Reviewed Reviewer Report
14 Apr 2021 Reviewed Reviewer Report
13 Jun 2021 Author responded Author comments - changlin li
Resubmission - Version 4
13 Jun 2021 Submitted Manuscript version 4
20 Jun 2021 Author responded Author comments - changlin li
Resubmission - Version 5
20 Jun 2021 Submitted Manuscript version 5
9 Jul 2021 Author responded Author comments - changlin li
Resubmission - Version 6
9 Jul 2021 Submitted Manuscript version 6
27 Jul 2021 Reviewed Reviewer Report
7 Aug 2021 Reviewed Reviewer Report
5 Sep 2021 Author responded Author comments - changlin li
Resubmission - Version 7
5 Sep 2021 Submitted Manuscript version 7
18 Sep 2021 Author responded Author comments - changlin li
Resubmission - Version 8
18 Sep 2021 Submitted Manuscript version 8
21 Sep 2021 Author responded Author comments - changlin li
Resubmission - Version 9
21 Sep 2021 Submitted Manuscript version 9
23 Sep 2021 Author responded Author comments - changlin li
Resubmission - Version 10
23 Sep 2021 Submitted Manuscript version 10
24 Sep 2021 Author responded Author comments - changlin li
Resubmission - Version 11
24 Sep 2021 Submitted Manuscript version 11
28 Sep 2021 Reviewed Reviewer Report
3 Oct 2021 Reviewed Reviewer Report
Resubmission - Version 12
Submitted Manuscript version 12
Publishing
5 Oct 2021 Editorially accepted
13 Oct 2021 Article published 10.1186/s12885-021-08841-1

You can find further information about peer review here.

Back to article page